QFM-3m: Anti-Inflammatory Activity in LPS-Induced Acute Lung Injury

A research document from figshare details the design and evaluation of a novel dihydrofurobenzofuran derivative, QFM-3m, for treating acute lung injury. The study, authored by Yuxi Wang and last updated in April 2026, includes in vitro screening in RAW264.7 macrophages and in vivo testing in a murine model, with mechanistic analysis via transcriptomics and western blot.

Use Cases

• Identify potential anti-inflammatory drug candidates based on the screening of rhodomentosone-like compounds.
• Study the molecular mechanism of MAPK pathway inhibition based on transcriptomic and protein analysis results.
• Validate in vivo efficacy for acute lung injury based on histopathology and cytokine assay data described.
• Perform structure-activity relationship analysis based on the design of dihydrofurobenzofuran derivatives.

Strengths

• The description provides specific molecular targets (ERK, JNK, p38) and measured cytokines (IL-1β, TNF-α, IL-6).
• Research methodology is explicitly outlined, including in vitro screening, murine model testing, and transcriptomic analysis.
• Dataset is openly licensed under CC-BY-4.0.

Limitations

• The dataset is a 12.8 KB DOCX file, indicating a very limited textual scope, likely a summary table or manuscript.
• Column-level documentation and sample data are unavailable, making direct data analysis impossible without the full document.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

figshare, author Yuxi Wang.

Collection Method

Likely contains summarized experimental results from pharmacological screening and molecular biology assays.

Freshness

Last updated 2026-04-21 04:13:00; freshness should be verified.